C12N 2770/24122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 412 US grants and 571 published applications in this corpus.
Search patents in C12N- Granted patents
- 412
- Published applications
- 571
- Assignees
- 311
- Inventors
- 995
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 2 | 0 |
| 1998 | 11 | 0 |
| 1999 | 6 | 0 |
| 2000 | 5 | 0 |
| 2001 | 6 | 0 |
| 2002 | 4 | 4 |
| 2003 | 7 | 12 |
| 2004 | 7 | 25 |
| 2005 | 5 | 19 |
| 2006 | 7 | 15 |
| 2007 | 5 | 19 |
| 2008 | 11 | 14 |
| 2009 | 15 | 29 |
| 2010 | 15 | 35 |
| 2011 | 19 | 34 |
| 2012 | 27 | 28 |
| 2013 | 12 | 18 |
| 2014 | 31 | 16 |
| 2015 | 21 | 21 |
| 2016 | 16 | 29 |
| 2017 | 8 | 28 |
| 2018 | 17 | 22 |
| 2019 | 26 | 35 |
| 2020 | 21 | 36 |
| 2021 | 20 | 34 |
| 2022 | 31 | 22 |
| 2023 | 17 | 19 |
| 2024 | 13 | 27 |
| 2025 | 12 | 19 |
| 2026 | 6 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Zika/dengue vaccine and application thereof2 Jun 2026US 12,642,846 B2Institute of Microbiology, Chinese Academy of Sciences
- Methods and compositions for the detection of host protein cleavage by group IV viral proteases21 Apr 2026US 12,607,633 B2The Government of the United States of America, as represented by the Secretary of the Navy
- Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development14 Apr 2026US 12,600,752 B2The University of North Carolina at Chapel Hill
- ZIKA antibodies and their use10 Mar 2026US 12,570,725 B2Duke University
- Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use17 Feb 2026US 12,553,893 B2Enable Biosciences Inc.
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof10 Sep 2026US 2026/0266820 A1Icahn School of Medicine at Mount Sinai
- Dengue vaccine3 Sep 2026US 2026/0256903 A1VLP Therapeutics, LLC
- Recombinant adenovirus comprising a polynucleotide encoding denv envelope protein and a polynucleotide encoding ferritin heavy chain protein, and uses thereof27 Aug 2026US 2026/0248902 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Dengue virus mrna vaccine and method against dengue virus infection using the same13 Aug 2026US 2026/0232788 A1Academia Sinica
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Hybrid molecules having translocation region and cell-binding region126US 5,668,255 ASeragen, Inc. · 1997
- Genetically engineered vaccine strain89US 5,364,773 AVirogenetics Corporation · 1994
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001